Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Ravi Vij; Thomas G. Martin; Nitya Nathwani; Mark A. Fiala; Feng Gao; Abhinav Deol; Francis K. Buadi; Jonathan L. Kaufman; Craig C Hofmeister; Tara K. Gregory; Jesus G. Berdeja; Ajai Chari; Ashley E. Rosko

doi:10.1182/BLOOD-2019-130644

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Ravi Vij
, Thomas G. Martin
, Nitya Nathwani
, Mark A. Fiala
, Feng Gao
, Abhinav Deol
, Francis K. Buadi
, Jonathan L. Kaufman
, Craig C Hofmeister
, Tara K. Gregory
, Jesus G. Berdeja
, Ajai Chari
, Ashley E. Rosko

Washington University in St. Louis
University of California, San Francisco
City of Hope National Medical Center
Wayne State University
Mayo Clinic
Emory University
Colorado Blood Cancer Institute, Denver, CO
Tennessee Oncology, Nashville, TN
Icahn School of Medicine at Mount Sinai
Ohio State University

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	134
DOIs	https://doi.org/10.1182/BLOOD-2019-130644
State	Published - Nov 13 2019
Externally published	Yes

Disciplines

Medicine and Health Sciences
Family Medicine

Access to Document

10.1182/BLOOD-2019-130644License: Unspecified

Cite this

Vij, R., Martin, T. G., Nathwani, N., Fiala, M. A., Gao, F., Deol, A., Buadi, F. K., Kaufman, J. L., Hofmeister, C. C., Gregory, T. K., Berdeja, J. G., Chari, A., & Rosko, A. E. (2019). Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial. Blood, 134. https://doi.org/10.1182/BLOOD-2019-130644

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial. / Vij, Ravi; Martin, Thomas G.; Nathwani, Nitya et al.
In: Blood, Vol. 134, 13.11.2019.

Research output: Contribution to journal › Article › peer-review

Vij, R, Martin, TG, Nathwani, N, Fiala, MA, Gao, F, Deol, A, Buadi, FK, Kaufman, JL, Hofmeister, CC, Gregory, TK, Berdeja, JG, Chari, A & Rosko, AE 2019, 'Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial', Blood, vol. 134. https://doi.org/10.1182/BLOOD-2019-130644

Vij R, Martin TG, Nathwani N, Fiala MA, Gao F, Deol A et al. Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial. Blood. 2019 Nov 13;134. doi: 10.1182/BLOOD-2019-130644

@article{285511da14e54027bde43a5caa943a17,

title = "Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial",

author = "Ravi Vij and Martin, \{Thomas G.\} and Nitya Nathwani and Fiala, \{Mark A.\} and Feng Gao and Abhinav Deol and Buadi, \{Francis K.\} and Kaufman, \{Jonathan L.\} and Hofmeister, \{Craig C\} and Gregory, \{Tara K.\} and Berdeja, \{Jesus G.\} and Ajai Chari and Rosko, \{Ashley E.\}",

note = "Ravi Vij, Thomas G. Martin, Nitya Nathwani, Mark A. Fiala, Feng Gao, Abhinav Deol, Francis K. Buadi, Jonathan L. Kaufman, Craig C Hofmeister, Tara K. Gregory, Jesus G. Berdeja, Ajai Chari, Ashley E. Rosko; Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial.",

year = "2019",

month = nov,

day = "13",

doi = "10.1182/BLOOD-2019-130644",

language = "American English",

volume = "134",

journal = "Blood",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

AU - Vij, Ravi

AU - Martin, Thomas G.

AU - Nathwani, Nitya

AU - Fiala, Mark A.

AU - Gao, Feng

AU - Deol, Abhinav

AU - Buadi, Francis K.

AU - Kaufman, Jonathan L.

AU - Hofmeister, Craig C

AU - Gregory, Tara K.

AU - Berdeja, Jesus G.

AU - Chari, Ajai

AU - Rosko, Ashley E.

N1 - Ravi Vij, Thomas G. Martin, Nitya Nathwani, Mark A. Fiala, Feng Gao, Abhinav Deol, Francis K. Buadi, Jonathan L. Kaufman, Craig C Hofmeister, Tara K. Gregory, Jesus G. Berdeja, Ajai Chari, Ashley E. Rosko; Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial.

PY - 2019/11/13

Y1 - 2019/11/13

UR - https://ashpublications.org/blood/article/134/Supplement_1/602/426431/Ixazomib-or-Lenalidomide-Maintenance-Following

U2 - 10.1182/BLOOD-2019-130644

DO - 10.1182/BLOOD-2019-130644

M3 - Article

VL - 134

JO - Blood

JF - Blood

ER -

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Disciplines

Access to Document

Other files and links

Cite this